COMPLETED

Network-guided TMS in Early Alzheimer's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed research will test a novel network-based neurostimulation approach using MRI-derived measures of brain connectivity to establish target sites for neurostimulation and test for the enhancement of memory function beyond a sham stimulation condition. This will be tested in cohort of MCI adults using network-based transcranial magnetic stimulation (TMS) to assess for behavioral improvement due to the controlled intervention. This study will provide important evidence towards the efficacy of neuromodulatory treatments for memory decline and will accelerate the discovery of potent non-invasive treatments to remediate cognitive decline in cognitively impaired older adults.

Official Title

Using Network-guided TMS to Ameliorate Memory Deficits in Early Alzheimer's Disease

Quick Facts

Study Start:2022-03-08
Study Completion:2025-06-27
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04549155

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:55 Years to 80 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Elderly: age between 55-80
  2. * English speaking
  3. * Willing to provide consent
  4. * Signed HIPAA authorization
  5. * Use of effective method of birth control for women of childbearing capacity
  6. * Clinical Consensus for MCI
  1. * History of any Axis I DSM-IV disorder
  2. * Current or past history of substance abuse or dependence (excluding nicotine)
  3. * Women who are pregnant or breast feeding
  4. * Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus Nerve stimulation device
  5. * Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 30 minutes.
  6. * Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm,
  7. * Dementia, Hungtington chorea; Multiple Sclerosis.
  8. * Current use of medications known to lower the seizure threshold and/or affect working memory
  9. * Current or past history of substance abuse or dependence (excluding nicotine)
  10. * Women who are pregnant or breast feeding

Contacts and Locations

Principal Investigator

Simon W Davis, PhD
PRINCIPAL_INVESTIGATOR
Duke University

Study Locations (Sites)

Duke University Medical Center
Durham, North Carolina, 27710
United States

Collaborators and Investigators

Sponsor: Duke University

  • Simon W Davis, PhD, PRINCIPAL_INVESTIGATOR, Duke University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-03-08
Study Completion Date2025-06-27

Study Record Updates

Study Start Date2022-03-08
Study Completion Date2025-06-27

Terms related to this study

Additional Relevant MeSH Terms

  • Mild Cognitive Impairment